Reader sentiment, not investment advice. One vote per visitor; click again to change it.
TEVA last changed hands at $39.23 (down 0.95%). At $45.75B, Teva Pharmaceutical Industries is ranked #332 by size among the 800 stocks on BeStock.
Over the past 52 weeks it has traded between $18.83 and $40.79, so it sits 3.8% below the top of that range.
Revenue for the quarter ended Jun 2026 was $4.14B, down 0.8% from a year earlier, and a net loss of $575.00M.
Valuation works out to 65.4 times trailing earnings. The median for its industry group is 30.5.
4 analysts follow the stock and the average call is "buy". The mean target, $45.00, sits 14.7% over where the stock trades.
This summary is put together from the numbers on the page and updates when they do. It describes the data; it is not a forecast or a recommendation.
Composite of 3 factors below, ranked against the 800 U.S. stocks BeStock covers.
Cheaper than usual on its own 5-year P/E history scores higher.
Trading closer to its 52-week high than most peers scores higher.
4 analysts, consensus Buy.
How this is scored: each factor above is a 0–100 percentile rank against every other stock BeStock covers (or, for Wall Street, against the five-point Strong Buy–Sell scale). The overall grade is the plain average of whichever factors apply to this stock — no factor is weighted more than another. That average maps to a letter: A ≥ 85, B ≥ 70, C ≥ 50, D ≥ 30, otherwise F. Recomputed from the data on this page as prices and filings update — it describes where a stock ranks today, not a forecast, and not a BeStock recommendation to buy or sell.
TEVA is not currently one of the 10 holdings in BeStock Momentum, our rules-based momentum strategy.
Since 2020-07-06, the strategy has returned 1524.8% (321.7% for the equal-weight average of BeStock’s coverage over the same stretch). Holdings can change any trading day, not just on a fixed schedule. Backtested performance, updated weekly — not a guarantee of future results, and not a BeStock recommendation.
What Wall Street analysts and Morningstar's fair-value model expect for the stock
Wall Street’s average 12-month target is $45.00, 14.7% above today’s price, with a consensus rating of Buy. Morningstar’s fair value model puts the stock at $42.00, so shares trade 6.6% below that estimate. On earnings multiple, it sits in the 100th percentile of its own five-year valuation range (pricier than usual).
Figures are Wall Street analyst consensus and Morningstar’s independent fair-value model, sourced as noted above.
Quote as of Oct 1, 2026 11:50 am ET. Prices can lag the live tape. This is background information, not a recommendation.
Ranks are among the 800 or so U.S.-listed stocks BeStock covers, recalculated whenever prices refresh. A tile is left out when the measure does not apply, such as yield for a stock that pays no dividend.
Set against the peer table: at 65.4x earnings, TEVA looks expensive against the market, and trades 114% above the 30.5x median among Drug Manufacturers - Specialty & Generic names. The two comparisons do not always agree.
$39.23 is the latest print for TEVA, a move of -0.95% against yesterday's close of $39.60. Today's low and high so far: $38.53 and $39.54.
Equity value comes to $45.75B at the current price. By that measure it is number 332 of the 800 names in our coverage.
Buyers pay 65.4 times the last twelve months of profit (EPS $1.21).
The year's floor is $18.83 and the ceiling $40.79. Shares are 3.8% away from that ceiling.
Our data shows no dividend paid by Teva Pharmaceutical Industries over the trailing twelve months.
Of 4 analysts, 100% say buy, 0% hold and 0% sell. Price targets average $45.00, with the most cautious at $42.00 and the most optimistic at $50.00.
BeStock publishes market data and analysis for information only. Nothing here is investment advice or a solicitation to buy or sell any security, and none of it is tailored to your financial situation, goals, or risk tolerance. Quotes may be delayed and figures can contain errors; check primary sources before you trade. How we source and calculate these pages.
No comments yet — be the first to weigh in on TEVA.